Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/1/2018
SIETES contiene 92186 citas

 
 
 1 a 20 de 177 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
2. Cita con resumen
Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]
3. Cita con resumen
Anónimo. Ramucirumab et cancer bronchique en 2e ligne. Prescrire 2017;37:337. [Ref.ID 101646]
4. Cita con resumen
Anónimo. Pertuzumab et cancers du sein métastasés. Prescrire 2017;37:94-5. [Ref.ID 101441]
5. Cita con resumen
Anónimo. Pertuzumab avant la chirurgie d'un cancer du sein. Prescrire 2017;37:92-4. [Ref.ID 101440]
6. Cita con resumen
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, de Marinis F, Turna H, Lee J-S, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. [Ref.ID 101392]
7. Cita con resumen
Anónimo. Érythrodysesthésies palmoplantaires des antitumoraux anti-VEGF. Prescrire 2017;37:30-1. [Ref.ID 101368]
8. Cita con resumen
Anónimo. Crizotinib en première ligne dans certains cancers bronchiques. Prescrire 2016;36:891-2. [Ref.ID 101005]
9. Cita con resumen
Anónimo. Nivolumab et cancer bronchique métastasé ou inopérable. Prescrire 2016;36:807-8. [Ref.ID 100948]
10. Cita con resumen
Anónimo. Nintédanib et cancer bronchique non à petites cellules. Prescrire 2016;36:178-9. [Ref.ID 100527]
11.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
12.Tiene citas relacionadas Cita con resumen
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A, POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46. [Ref.ID 100249]
13.Tiene citas relacionadas
Smit EF, van den Heuvel MM. PD-L1 in non-small-cell lung cancer: the third target for immunotherapy. Lancet 2016;387:1795-6. [Ref.ID 100247]
14.
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, Majem M, Fidler MJ, de Castro Jr G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. [Ref.ID 100227]
15. Cita con resumen
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AWS, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sulllivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MKB, STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77. [Ref.ID 100158]
16. Cita con resumen
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:125-35. [Ref.ID 99339]
17. Cita con resumen
Anónimo. Afatinib. Prescrire 2015;35:92-3. [Ref.ID 98909]
18. Cita con resumen
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, for the CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34. [Ref.ID 98817]
20. Cita con resumen
Anónimo. Pertes d'auditions d'origine médicamenteuse. Prescrire 2014;34:428-35. [Ref.ID 97948]
Seleccionar todas
 
 1 a 20 de 177 siguiente >>